FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Peter Wunderli
Advertisement
Articles by Peter Wunderli
Advertisement
Latest Updated Articles
Viral Vector API Characterization of Product-Related ImpuritiesOctober 15th 2020
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires
5